Pembrolizumab + Placebo for pembrolizumab + Cisplatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Cervical Neoplasms
Conditions
Uterine Cervical Neoplasms
Trial Timeline
May 12, 2020 → Jan 26, 2026
NCT ID
NCT04221945About Pembrolizumab + Placebo for pembrolizumab + Cisplatin
Pembrolizumab + Placebo for pembrolizumab + Cisplatin is a phase 3 stage product being developed by Merck for Uterine Cervical Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT04221945. Target conditions include Uterine Cervical Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04221945 | Phase 3 | Completed |
Competing Products
20 competing products in Uterine Cervical Neoplasms